[
  {
    "pmid": "40671491",
    "citation": "Bradley Rockwell et al. Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.. Haematologica (2025 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40671491/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "title",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) was found in the provided title.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40524338",
    "citation": "Michael R Savona et al. Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.. British journal of haematology (2025 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40524338/",
    "drug": "decitabine",
    "complete_response": 21.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 76.0,
    "progression_free_survival_median": 28.3,
    "overall_survival_median": 35.7,
    "total_patients": 33,
    "cmml_patients": 33,
    "supporting_quotes": [
      "The overall response rate was 76%, with 21% (n\u2009=\u20097) of patients achieving a complete response.",
      "Median overall and transformation-free survival were 35.7 and 28.3\u2009months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study showed an overall response rate of 76% in 33 CMML patients treated with decitabine/cedazuridine, with a 21% complete response rate. Median overall survival was 35.7 months, and median transformation-free survival was 28.3 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "40453133",
    "citation": "Patricia L Kropf et al. A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.. Blood neoplasia (2025 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40453133/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 30,
    "cmml_patients": null,
    "supporting_quotes": [
      "Thirty patients were initially randomized to receive DAC alone (20 mg/m"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract only mentions that the study was conducted and the number of patients randomized; no efficacy data (response rates or survival data) for MDS or AML is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40415500",
    "citation": "Jowan Al-Nusair et al. Nodal Mature Plasmacytoid Dendritic Cell Proliferation in a Patient With Chronic Myelomonocytic Leukemia: A Diagnostic Mimic of Blastic Plasmacytoid Dendritic Cell Neoplasm.. Journal of investigative medicine high impact case reports (2025)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40415500/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We report a 78-year-old male with CMML-1 and progressive cervical lymphadenopathy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on a single patient with CMML.  No response rates or survival data are provided. The patient received hydroxyurea and later decitabine/cedazuridine, but no information on efficacy is given beyond noting that the CMML remained stable at follow-up.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40164584",
    "citation": "Alex Bataller et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.. Blood cancer journal (2025 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40164584/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": {
      "DEC-C": 64.0,
      "DEC-C-Ven": 90.0
    },
    "progression_free_survival_median": {
      "DEC-C": 10.0,
      "DEC-C-Ven": 18.0
    },
    "overall_survival_median": {
      "DEC-C": 19.0,
      "DEC-C-Ven": 24.0
    },
    "total_patients": 124,
    "cmml_patients": 20,
    "supporting_quotes": [
      "The overall response rate was superior in the DEC-C-Ven cohort (90% vs 64%, P\u2009=\u20090.002).",
      "The median times to best response were 1.1 and 2.7 months for the DEC-C-Ven and DEC-C cohorts, respectively (P\u2009<\u20090.001).",
      "The median overall survival was 24 and 19 months for the DEC-C-Ven and DEC-C cohorts, respectively (P\u2009=\u20090.89), and the median event-free survival durations were 18 and 10 months (P\u2009=\u20090.026)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The addition of venetoclax to decitabine-cedazuridine improved overall response rate (90% vs 64%),  progression-free survival (18 months vs 10 months), although overall survival difference was not statistically significant (24 months vs 19 months).",
    "has_efficacy_data": true
  },
  {
    "pmid": "40051275",
    "citation": "Guillermo Garcia-Manero et al. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.. Future oncology (London, England) (2025 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40051275/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39734743",
    "citation": "Anthony Crymes et al. Acute Myeloid Leukemia (AML) With T-Cell Differentiation Arising From Chronic Myelomonocytic Leukemia (CMML).. Case reports in hematology (2024)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39734743/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We present a 58-year-old woman with a past medical history of idiopathic thrombocytopenic purpura (ITP) who demonstrated 24% bone marrow blasts on a repeat biopsy obtained two years after being diagnosed with CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case study of a CMML patient who progressed to AML.  Treatment with multiple agents, including decitabine, cytarabine, daunorubicin, etoposide, venetoclax, and two experimental BET inhibitors, did not result in sustained remission.  No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39300079",
    "citation": "Hagop Kantarjian et al. Current status and research directions in acute myeloid leukemia.. Blood cancer journal (2024 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39300079/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any clinical efficacy data (response rates or survival data) for CMML or AML.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39024804",
    "citation": "Kaiyue Wang et al. Targeting DNA methyltransferases for cancer therapy.. Bioorganic chemistry (2024 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39024804/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions that Azacytidine and Decitabine are FDA and EMA approved for CMML treatment, but provides no specific clinical efficacy data such as response rates or survival times.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40454402",
    "citation": "Samuel Urrutia et al. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML.. Blood neoplasia (2024 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40454402/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 100,
    "cmml_patients": null,
    "supporting_quotes": [
      "Of 100 enrolled patients, 82% had MDS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract only provides the total number of patients enrolled (100) and the percentage with MDS (82%). No response rates or survival data are reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38450850",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.. American journal of hematology (2024 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38450850/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 23.1,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "a recent phase-3 study (DACOTA) comparing hydroxyurea and decitabine, in high-risk MP-CMML, showed similar overall survival at 23.1 versus 18.4 months, respectively, despite response rates being higher for decitabine (56% vs. 31%)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The DACOTA study showed an overall survival of 23.1 months for patients receiving hydroxyurea and 18.4 months for those receiving decitabine in high-risk MP-CMML.  Response rates were higher with decitabine (56%) compared to hydroxyurea (31%), although specific response types (CR, PR, mCR, ORR) are not detailed.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38387931",
    "citation": "Xiao Li et al. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].. Zhongguo shi yan xue ye xue za zhi (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38387931/",
    "drug": "decitabine",
    "complete_response": 28.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 80.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 17.4,
    "total_patients": 25,
    "cmml_patients": 25,
    "supporting_quotes": [
      "Among them, 20 patients responded, and 7 patients got complete remission (CR).",
      "All patients with CR were treated with DEC as the basic treatment.",
      "After a median follow-up of 16.4 (9.4-20.5) months, 4 patients with CR progressed to acute myeloid leukemia (AML).",
      "The median overall survival (OS) time of 25 CMML patients was 17.4 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an 80% overall response rate with a 28% complete remission rate among 25 CMML patients treated with hypomethylating agents. Median overall survival was 17.4 months.  Progression to AML was observed in some patients who achieved CR.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38316134",
    "citation": "Sarit Assouline Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.. The Lancet. Haematology (2024 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38316134/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival metrics) for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38316133",
    "citation": "Alex Bataller et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.. The Lancet. Haematology (2024 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38316133/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 95.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 39,
    "cmml_patients": null,
    "supporting_quotes": [
      "The overall response rate was 95% (95% CI 83-99; 37/39).",
      "Between Jan 21, 2021, and Jan 20, 2023, we enrolled 39 patients (nine in phase 1 and 30 in phase 2)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed a high overall response rate (ORR) of 95% in 39 patients.  However,  no data on complete response, partial response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38135371",
    "citation": "Guillermo Garcia-Manero et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.. The Lancet. Haematology (2024 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38135371/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 133,
    "cmml_patients": null,
    "supporting_quotes": [
      "In 37 academic and community-based clinics in Canada and the USA, we enrolled individuals aged 18 years or older who were candidates to receive intravenous decitabine, with Eastern Cooperative Oncology Group performance status 0 or 1 and a life expectancy of at least 3 months.",
      "Between Feb 8, 2018, and June 7, 2021, 173 individuals were screened, 138 (80%) participants were randomly assigned to a treatment sequence, and 133 (96%) participants (87 [65%] men and 46 [35%] women; 121 [91%] White, four [3%] Black or African-American, three [2%] Asian, and five [4%] not reported) received treatment.",
      "Median follow-up was 966 days (IQR 917-1050)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on comparing the pharmacokinetics and safety of oral and intravenous decitabine, finding them to be equivalent.  No response rates or survival data are explicitly provided in the abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37994196",
    "citation": "Andrew M Brunner et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.. American journal of hematology (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37994196/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions durable clinical responses in HR/vHR-MDS patients but provides no specific efficacy metrics (response rates or survival data) for either MDS or CMML.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37754496",
    "citation": "John Paul Yun et al. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.. Current oncology (Toronto, Ont.) (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37754496/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": 10.7,
    "overall_survival_median": 21.6,
    "total_patients": 769,
    "cmml_patients": null,
    "supporting_quotes": [
      "The median overall and progression-free survival were 21.6 and 10.7 months, respectively.",
      "Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada's Patient Support Program were collected and analyzed."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports median overall survival (OS) of 21.6 months and median progression-free survival (PFS) of 10.7 months for 651 patients who started treatment with DEC-C.  Response rates were not reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "37546162",
    "citation": "Anwarul Islam An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.. Clinical case reports (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37546162/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Our report describes a patient with CMML who not only did not respond to a conventional dose of intravenous (IV) therapy with AZA, but showed marked progression of the disease with the leucocyte count rising exponentially while undergoing the aforesaid treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study describes a single CMML patient who showed disease progression during treatment with 5-azacitidine. No response rates or survival data were provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37495538",
    "citation": "Tomoyuki Saga et al. Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.. Internal medicine (Tokyo, Japan) (2024 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37495538/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13.0,
    "total_patients": 29,
    "cmml_patients": 5,
    "supporting_quotes": [
      "Patients Twenty-nine patients were included",
      "chronic myelomonocytic leukemia (n=5)",
      "The median follow-up duration was 13.0 (range 1.5-93.5) months.",
      "The HbF-elevated group was associated with a significantly higher hematologic improvement rate (76.9% vs. 25%, p=0.009) and better overall survival (median, 21.0 vs. 13.0 months, p=0.048) than the HbF-normal group."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows that elevated pretreatment HbF levels correlate with a higher hematologic improvement rate (76.9% vs 25%) and better overall survival (median 21.0 vs 13.0 months) in patients with MDS/AML treated with azacitidine.  Specific response rates (CR, PR, mCR, ORR) are not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "37409458",
    "citation": "Xiaofei Song et al. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.. Platelets (2023 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37409458/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 108,
    "cmml_patients": null,
    "supporting_quotes": [
      "We reviewed 108 patients with hematological diseases including acute leukemia, myelodysplastic syndrome, aplastic anemia, and others who received allogeneic hematopoietic stem cell transplantation (HSCT) from January 2019 through December 2020."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study focuses on platelet transfusion refractoriness and its impact on hematopoietic stem cell transplantation outcomes in various hematological diseases.  No CMML-specific data or treatment efficacy metrics (response rates or survival data) are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37341641",
    "citation": "David Levitz et al. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.. Clinical cancer research : an official journal of the American Association for Cancer Research (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37341641/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 10.7,
    "total_patients": 75,
    "cmml_patients": null,
    "supporting_quotes": [
      "In a retrospective cohort of 39 patients, the overall response rate for patients receiving LDDec/VEN for first-line AML and MDS was 88% and 64%, respectively.",
      "In patients with TP53 mutations, the composite complete response rate was 71% and the median overall survival was 10.7 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports overall response rates of 88% and 64% for AML and MDS patients respectively, treated with LDDec/VEN.  A 71% composite complete response rate and a median overall survival of 10.7 months were observed in patients with TP53 mutations.  The total number of patients was 39 for the LDDec/VEN arm and an additional 36 in the standard dose HMA/VEN arm.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36845813",
    "citation": "Shekhar Gurung et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.. Annals of medicine and surgery (2012) (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Herein, the authors report a case of CMML in a 72-year-old male"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "No efficacy data (response rates or survival data) is reported for the treatment given to the single patient in this case report.  Only the planned treatment is mentioned.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36801588",
    "citation": "Tugcan Alp Kirkizlar et al. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.. Leukemia research (2023 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36801588/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 7.8,
    "total_patients": 43,
    "cmml_patients": 3,
    "supporting_quotes": [
      "43 adult patients with AML or high-risk MDS or CMML who received HMA \u2265 2 consecutive cycles from January 2014 to December 2020 were enrolled in the study.",
      "CMML in 3 patients (7 %)",
      "The median survival was 7.8 months in non-infected cycles while 6.83 months in infected cycles."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 7.8 months in non-infected patients and 6.83 months in infected patients treated with hypomethylating agents.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36653885",
    "citation": "Ankur Sheel et al. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report.. Cardio-oncology (London, England) (2023 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36653885/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": 1,
    "supporting_quotes": [
      "This case study presents an 85\u2009year-old\u00a0Caucasian\u00a0female with CMML who developed cardiomyopathy and heart failure with reduced ejection fraction after completing 5\u2009cycles of therapy with decitabine/cedazuridine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of a CMML patient experiencing reversible cardiomyopathy after treatment with decitabine/cedazuridine. No overall response rates or survival data were provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36479336",
    "citation": "Unknown authors Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes.. Australian prescriber (2022 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36479336/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36455187",
    "citation": "Raphael Itzykson et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 170,
    "cmml_patients": null,
    "supporting_quotes": [
      "One-hundred seventy patients received DAC (n = 84) or HY (n = 86).",
      "Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found that decitabine did not improve progression-free survival compared to hydroxyurea in patients with advanced myeloproliferative CMML.  No response rates or overall survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36338706",
    "citation": "Kefeng Shen et al. Inherited heterozygous Fanconi anemia gene mutations in a therapy-related CMML patient with a rare . Frontiers in oncology (2022)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36338706/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We report a female patient who suffered from ovarian cancer at 50 years of age.",
      "Unfortunately, at 54 years of age, she developed a secondary cancer of therapy-related (t-) chronic myelomonocytic leukemia (t-CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on a single case of therapy-related CMML.  No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36150563",
    "citation": "Faezeh Darbaniyan et al. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Experimental hematology (2022 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36150563/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35707788",
    "citation": "Xinhui Zheng et al. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.. Global medical genetics (2022 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35707788/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data (response rates or survival metrics) was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35656122",
    "citation": "Priyanka Lakshmanan et al. Central Diabetes Insipidus Induced by Acute Myeloid Leukemia with DNMT3A Mutation.. Case reports in endocrinology (2022)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35656122/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe the case of a 36-year-old male who presented with a subacute onset of polyuria, polydipsia, nocturia, and fatigue.",
      "After an extensive workup, he was diagnosed with AML/CMML (chronic myelomonocytic leukemia) with a normal karyotype with DNMT3A, CBFB, and PTPN11 mutations.",
      "He is in minimal residual disease (MRD)-negative complete remission after induction with a CNS-active acute lymphoblastic leukemia-2 regimen."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of a patient with AML/CMML who achieved MRD-negative complete remission after receiving a specific treatment regimen.  No overall response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35093134",
    "citation": "Nicholas J Short et al. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.. Journal of hematology & oncology (2022 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35093134/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13.7,
    "total_patients": 562,
    "cmml_patients": null,
    "supporting_quotes": [
      "Compared with IC or LIT without venetoclax, HMA plus venetoclax resulted in higher CR/CRi rates (39% and 25%, respectively; P\u2009=\u20090.02) and superior OS (1-year OS 34% and 17%, respectively; P\u2009=\u20090.05).",
      "The benefit of HMA plus venetoclax was restricted to patients with non-adverse risk karyotype, where HMA plus venetoclax resulted in a median OS of 13.7\u00a0months and 1-year OS rate of 54%; in contrast, for patients with adverse risk karyotype, OS was similarly dismal regardless of treatment approach (median OS 3-5\u00a0months)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows that HMA plus venetoclax resulted in higher CR/CRi rates (39% and 25%) and superior OS compared to other treatments.  A median OS of 13.7 months was observed in patients with non-adverse risk karyotype receiving HMA plus venetoclax.  The study focuses on secondary AML, with CMML being one of the antecedent hematologic disorders, but doesn't provide separate efficacy data for CMML patients.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34985762",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.. American journal of hematology (2022 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
    "drug": "decitabine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 47.5,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The abstract reports overall response rates of approximately 40-50% for hypomethylating agents like 5-azacitidine and decitabine in treating CMML, with complete remission rates around 7-17%.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34966690",
    "citation": "Konstantinos Liapis et al. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in oncology (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34966690/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No quantitative clinical efficacy data (response rates or survival data)  was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34687602",
    "citation": "Hagop Kantarjian et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.. The Lancet. Haematology (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34687602/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions the approval of decitabine for CMML, but provides no specific clinical efficacy data (response rates or survival data) for CMML patients treated with this or any other drug.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34558354",
    "citation": "Katie Xu et al. Novel agents for myelodysplastic syndromes.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34558354/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The novel myelodysplastic syndromes agents luspatercept-aamt and decitabine/cedazuridine provide a clinical benefit in the studied populations."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions that luspatercept-aamt and decitabine/cedazuridine provide a clinical benefit, but no specific efficacy metrics like response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34233332",
    "citation": "Hee Sue Park et al. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.. Acta haematologica (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34233332/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 33.9,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 59,
    "cmml_patients": null,
    "supporting_quotes": [
      "The overall response rate to HMAs was 33.9%",
      "We performed next-generation sequencing on bone marrow aspiration samples of 59 patients diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2, or chronic myelomonocytic leukemia and treated with decitabine or azacitidine as a frontline therapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 33.9% to hypomethylating agents (HMAs) in patients with myeloid neoplasms, including CMML.  No data on specific response types (CR, PR, mCR) or survival metrics (PFS, OS) is provided.  Mutations in RAS pathway-related genes were associated with a poorer response to HMAs, and NRAS mutations predicted inferior survival.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34175902",
    "citation": "Aline Renneville et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.. Leukemia (2021 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34175902/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Median overall survival of this aggressive myeloid malignancy is only 2-3 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median overall survival of 2-3 years (24-36 months).  No other response rates or survival metrics are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33904891",
    "citation": "Anand A Patel et al. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.. Blood advances (2021 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33904891/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions FDA approval of C-DEC for CMML based on phase 3 trial results showing bioequivalence to parenteral decitabine, but it does not provide specific efficacy metrics like response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33878941",
    "citation": "Pasquale Niscola et al. New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine.. Future oncology (London, England) (2021 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33878941/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33869012",
    "citation": "MinMing Li et al. Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients.. Frontiers in oncology (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33869012/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 14.3,
    "total_patients": 22,
    "cmml_patients": null,
    "supporting_quotes": [
      "The median overall survival (OS) of the MST-DAC group was higher than that of the DAC group (24 vs. 14.3 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 14.3 months for the decitabine-only group.  No other response rates or survival metrics are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33853476",
    "citation": "Molly Schiffer et al. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.. Expert review of anticancer therapy (2021 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33853476/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions that ASTX727 is approved for CMML treatment based on the ASTX727-01-B and ASCERTAIN trials, and that oral azacitidine (CC-486) is approved for AML maintenance treatment based on the QUAZAR AML-001 trial. However, no specific efficacy data (response rates or survival data) from these trials are provided in the abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33807279",
    "citation": "Jan Philipp Bewersdorf et al. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).. Cancers (2021 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33807279/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide specific clinical efficacy metrics (response rates or survival data) for CMML or MDS treatments.  It mentions that azacitidine showed an overall survival benefit but doesn't quantify it.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33792103",
    "citation": "Douglas Tremblay et al. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.. The oncologist (2021 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33792103/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any specific clinical efficacy data such as response rates or survival metrics for CMML treatments.  The text focuses on describing available treatments and risk stratification.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33769069",
    "citation": "David Kipp et al. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.. Future oncology (London, England) (2021 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33769069/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "This article briefly summarizes the clinical development of both drugs, the pivotal studies that led to their approval and some of the issues faced in extending the use of these drugs to other indications.",
      "CC-486 has been shown to improve overall survival as maintenance therapy for older patients with acute myeloid leukemia in complete remission, whereas the combination of decitabine with cedazuridine, a cytidine deaminase inhibitor, is indicated for the treatment of adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia with intermediate-1, or higher, International Prognostic Scoring System risk."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract mentions the approval of two drugs based on clinical trials but provides no specific efficacy metrics (response rates, survival data, or patient numbers) for CMML.  It only states that one drug combination is indicated for CMML treatment based on a risk assessment system.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33709786",
    "citation": "Swapna Thota et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Future oncology (London, England) (2021 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33709786/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide specific clinical efficacy metrics (response rates or survival data) for CMML treatment with C-DEC.  It only mentions the drug's approval and the limitations of existing therapies.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33706667",
    "citation": "Ruohao Xu et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33706667/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": 23.0,
    "overall_response_rate": 43.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 600,
    "cmml_patients": 600,
    "supporting_quotes": [
      "HMAs yielded a pooled ORR estimate of 43% (95% CI: 36%-50%) in patients with CMML.",
      "Patients received either azacitidine or decitabine exhibited comparable incidence of ORR (43% vs. 45%, P=0.810), while significantly higher incidence of mCR was observed in patients treated with decitabine (23% vs. 10%, P=0.000).",
      "Fourteen studies with 600 CMML patients (decitabine: n=196; azacitidine: n=404) were identified and included for meta-analysis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The meta-analysis of 600 CMML patients treated with hypomethylating agents (HMAs) showed an overall response rate (ORR) of 43%.  Decitabine demonstrated a higher marrow complete response (mCR) rate (23%) compared to azacitidine (10%).",
    "has_efficacy_data": true
  },
  {
    "pmid": "33644180",
    "citation": "Can Chen et al. Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature.. World journal of clinical cases (2021 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33644180/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "To the best of our knowledge, this is the first reported case of PAP occurring secondary to CMML.",
      "We report the case of a 63-year-old male who presented with a recurrent cough and gradually progressive dyspnea in the absence of fever.",
      "The patient died in January 2020 as a consequence of severe pulmonary infection."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study is a single case report, providing no quantifiable efficacy data on CMML treatment.  The patient received treatment but died of a pulmonary infection after nearly four years.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33407852",
    "citation": "Johannes Lorenz Berg et al. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.. Clinical epigenetics (2021 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33407852/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any clinical efficacy data such as response rates or survival metrics.  The study focuses on the role of micro-RNA-125a in mediating the effects of hypomethylating agents, not on reporting the clinical outcomes of these agents in CMML patients.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33369023",
    "citation": "John C Molina et al. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.. Pediatric blood & cancer (2021 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33369023/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe an adolescent with monosomy 7 CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of CMML treated with venetoclax and decitabine.  No quantitative efficacy data (response rates or survival) is provided, only qualitative description of effectiveness as \"effective for treatment of CMML as a bridge to HSCT\".",
    "has_efficacy_data": false
  },
  {
    "pmid": "33280448",
    "citation": "Jorge Ramos Perez et al. Emerging drugs for the treatment of chronic myelomonocytic leukemia.. Expert opinion on emerging drugs (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33280448/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33275673",
    "citation": "Mrinal M Patnaik et al. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.. Hematology. American Society of Hematology. Education Program (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 36.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "CMML usually presents in the 7th decade of life, with a male preponderance and is associated with a median overall survival of <36 months.",
      "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML, with overall response rates of 40-50% and complete remission rates of <20%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The median overall survival for CMML is less than 36 months.  Overall response rates to hypomethylating agents (azacitidine, decitabine, and oral decitabine/cedazuridine) are in the 40-50% range, with complete remission rates below 20%.  No data on progression-free survival, partial response, or marrow complete response is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33255988",
    "citation": "Fabio Forghieri et al. . International journal of molecular sciences (2020 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33255988/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data related to CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "32896301",
    "citation": "Courtney D DiNardo et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.. The Lancet. Haematology (2020 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32896301/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 74.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 168,
    "cmml_patients": null,
    "supporting_quotes": [
      "The overall response rate was 74% (125 of 168 patients; 95% CI 67-80) and in disease subgroups were: 89% in newly diagnosed AML (62 of 70 patients; 79-94), 80% in untreated secondary AML (12 of 15 patients; 55-93), 61% in treated secondary AML (17 of 28 patients; 42-76), and 62% in relapsed or refractory AML (34 of 55 patients; 49-74).",
      "The median overall survival was 18\u00b71 months (95% CI 10\u00b70-not reached) in newly diagnosed AML, 7\u00b78 months (2\u00b79-10\u00b77) in untreated secondary AML, 6\u00b70 months (3\u00b74-13\u00b77) in treated secondary AML, and 7\u00b78 months (5\u00b74-13\u00b73) relapsed or refractory AML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 74% across all patient groups.  Survival data varied across subgroups, with median overall survival ranging from 6.0 to 18.1 months depending on the AML subtype.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32860582",
    "citation": "Sohita Dhillon Decitabine/Cedazuridine: First Approval.. Drugs (2020 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32860582/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "32285126",
    "citation": "Guillermo Garcia-Manero et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.. Blood (2020 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32285126/",
    "drug": "decitabine",
    "complete_response": 21.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 80,
    "cmml_patients": null,
    "supporting_quotes": [
      "Clinical responses were observed in 48 patients (60%), including 17 (21%) with complete response."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 60% with a complete response rate of 21%.  No data on partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31736132",
    "citation": "Mrinal M Patnaik et al. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.. American journal of hematology (2020 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31736132/",
    "drug": "decitabine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 47.5,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The abstract reports overall response rates of approximately 47.5% (median of 40-50%) and complete remission rates of approximately 7-17% for hypomethylating agents like 5-azacitidine and decitabine.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31623402",
    "citation": "Vanessa Kohl et al. Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.. Cancers (2019 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31623402/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any clinical efficacy data such as response rates or survival metrics for CMML patients.  The study focuses on in vitro cytotoxic efficacy, not clinical trial results.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31559392",
    "citation": "Abhishek A Mangaonkar et al. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.. Advances in cell and gene therapy (2019 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31559392/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Outcomes remain uniformly poor with a median overall survival of ~2 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The abstract reports a median overall survival of 24 months (2 years).  No other efficacy data such as response rates or progression-free survival are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31494229",
    "citation": "Yi-Geng Cao et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2020 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31494229/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 48,
    "cmml_patients": 4,
    "supporting_quotes": [
      "A total of 48 patients were enrolled, including 44 with MDS and 4 with chronic myelomonocytic leukemia (CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The provided text only reports the total number of patients enrolled in the study and the number of patients with CMML.  No response rates or survival data are available.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31340618",
    "citation": "X L Zhao et al. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2019 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31340618/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31060979",
    "citation": "Guillermo Garcia-Manero et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.. The Lancet. Haematology (2019 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31060979/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 105,
    "cmml_patients": null,
    "supporting_quotes": [
      "Between July 9, 2012, and April 7, 2014, 105 patients were enrolled"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study mentions that guadecitabine was clinically active with acceptable tolerability but does not provide specific response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31020568",
    "citation": "Matthieu Duchmann et al. Clinical update on hypomethylating agents.. International journal of hematology (2019 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31020568/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions that the clinical activity of HMAs in myeloid neoplasms is established but of limited magnitude,  but provides no specific efficacy metrics for CMML or any other myeloid neoplasm.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30964202",
    "citation": "Tucker Coston et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.. American journal of hematology (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30964202/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 31.0,
    "total_patients": 121,
    "cmml_patients": 121,
    "supporting_quotes": [
      "The overall response rates were 41% by the IWG MDS (AZA- 45%, DAC-39%), and 56% by the IWG MDS/MPN (AZA-56%, DAC-58%) response criteria, with CR (complete remission) rates of <20% for both agents, by both criteria.",
      "HMA treated patients had a longer median OS (31 vs 18 months; P = .01), in comparison to those treated with conventional care regimens (excluding observation only patients), without any differences between AZA vs DAC (P = .37)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Overall response rates to hypomethylating agents (HMA) in CMML were 41% using IWG MDS criteria and 56% using IWG MDS/MPN criteria.  Complete remission rates were below 20%. Median overall survival was 31 months for patients treated with HMA, significantly longer than those receiving conventional care (18 months).  Progression after response was associated with a median OS of 8 months, and median OS in patients with primary HMA failure was 4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30926081",
    "citation": "Michael R Savona et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.. The Lancet. Haematology (2019 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30926081/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 44,
    "cmml_patients": null,
    "supporting_quotes": [
      "Between Oct 28, 2014, and Nov 13, 2015, we enrolled 44 eligible patients (of 75 screened) with previously treated or newly diagnosed myelodysplastic syndromes or chronic myelomonocytic leukaemia; 43 of the enrolled patients were evaluable."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions 44 total patients enrolled, but it does not provide specific response rates or survival data for CMML patients or the overall study population.  The focus is on the pharmacokinetic and safety profile of the drug combination.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30579366",
    "citation": "Paola Orsini et al. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.. Diagnostic pathology (2018 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30579366/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 46,
    "cmml_patients": 9,
    "supporting_quotes": [
      "Forty-six patients with hematological neoplasms were included in the study: 30 patients affected by chronic lymphocytic leukemia, 7 patients with myelodysplastic syndromes at intermediate/high risk, and 9 patients with myelomonocytic leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study did not report response rates or survival data.  It only presents the number of patients with CMML and the observation of decreased Alu methylation in a subset of CMML patients with a specific gene mutation.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30367269",
    "citation": "Anthony M Hunter et al. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.. Current treatment options in oncology (2018 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30367269/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide any specific clinical efficacy metrics such as response rates or survival data.  It discusses treatment approaches and their potential, but lacks quantitative results from clinical trials.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29878489",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.. American journal of hematology (2018 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29878489/",
    "drug": "decitabine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of \u223c30%-40% and complete remission rates of \u223c7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The abstract reports overall response rates of 30-40% for hypomethylating agents, with complete remission rates of 7-17%.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29731877",
    "citation": "Huan Liu et al. Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.. Oncology letters (2018 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29731877/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "The present study describes a patient with high-risk chronic myelomonocytic leukemia (CMML), for whom decitabine therapy achieved partial remission",
      "Partial remission was achieved with decitabine treatment, and hematologic improvement was observed subsequent to 2 cycles of treatment. However, a sudden transformation to AML led to fatality of the patient."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of high-risk CMML achieving partial remission with decitabine, but ultimately transforming to AML and resulting in death.  No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29728305",
    "citation": "Matthieu Duchmann et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.. EBioMedicine (2018 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29728305/",
    "drug": "decitabine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 52.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 174,
    "cmml_patients": 174,
    "supporting_quotes": [
      "Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%).",
      "We analyzed a retrospective multi-center cohort of 174 CMML patients"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found an overall response rate of 52% with a complete response rate of 17% in 174 CMML patients treated with hypomethylating agents.  No PFS or OS data was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29588547",
    "citation": "Hein Than et al. Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.. Leukemia (2018 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29588547/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival metrics) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29069007",
    "citation": "Yayue Gao et al. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.. Medicine (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29069007/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 100.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 2,
    "supporting_quotes": [
      "In both patients, the platelet counts returned to the normal within 1 week after eltrombopag therapy.",
      "The platelet count in case 1 patient remained stable at 141-200 \u00d7 10/L for 20 months with stopping therapy for 3 months.",
      "In case 2 patient, eltrombopag was stopped 1 month later. Her platelet count decreased to 41 \u00d7 10/L, but was stable at \u223c30 \u00d7 10/L for 3 months with platelet transfusion independency for 12 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Both patients with CMML and thrombocytopenia showed a rapid and positive response to eltrombopag treatment, with platelet counts returning to normal within one week.  Long-term follow-up showed sustained improvement, although one patient eventually experienced a decrease in platelet count after treatment cessation.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28774880",
    "citation": "Elias Jabbour et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.. Blood (2017 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28774880/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any specific clinical efficacy metrics (response rates or survival data).  It only mentions the study design and patient populations.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28621841",
    "citation": "Amer M Zeidan et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.. Cancer (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28621841/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13,
    "total_patients": 1378,
    "cmml_patients": 1378,
    "supporting_quotes": [
      "Among 1378 older adults diagnosed with CMML, the median OS was 13 months",
      "In the primary matched analysis, with 225 HMA users diagnosed in 2007-2011 and 395 patients diagnosed in 2001-2003, the median OS times were 17 and 11 months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found a median overall survival (OS) of 13 months for all 1378 older adults with CMML.  In a matched analysis comparing patients who received hypomethylating agents (HMAs) after their approval with those diagnosed before, the median OS was 17 months for the HMA group and 11 months for the control group. This represents a statistically significant improvement in survival with HMA use.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28607470",
    "citation": "V Santini et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.. Leukemia (2018 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28607470/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain specific clinical efficacy data such as response rates or survival metrics.  It only describes the study design and rationale.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28498370",
    "citation": "M Duchmann et al. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.. Blood cancer journal (2017 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28498370/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data (response rates or survival metrics) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28370097",
    "citation": "Ana Alfonso et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.. American journal of hematology (2017 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28370097/",
    "drug": "decitabine",
    "complete_response": 41.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 75.0,
    "progression_free_survival_median": 14.0,
    "overall_survival_median": 24.0,
    "total_patients": 151,
    "cmml_patients": 151,
    "supporting_quotes": [
      "With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR).",
      "Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17).",
      "We present the largest retrospective series of CMML (n\u2009=\u2009151) treated with HMA."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Hypomethylating agents (HMA) showed an overall response rate of 75% in 151 CMML patients, with a complete response rate of 41%. Median overall survival was 24 months, and median event-free survival was 14 months.  Decitabine showed a significantly higher complete response rate (58.3%) compared to azacitidine (20.6%). Outcomes after HMA failure were poor.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28359286",
    "citation": "Florian Wolff et al. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.. Cell communication and signaling : CCS (2017 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28359286/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment is presented in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28102729",
    "citation": "Jia Gu et al. Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.. Cancer biology & therapy (2017 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28102729/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We reported a 51-year-old man who had CMML with concomitant mutations in DNMT3A and FLT3-ITD."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of a CMML patient with double mutations treated with decitabine and sorafenib. No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27849645",
    "citation": "Ana Alfonso et al. Current management of patients with chronic myelomonocytic leukemia.. Current opinion in oncology (2017 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27849645/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide specific clinical efficacy data such as response rates or survival metrics for CMML treatments.  It only discusses treatment options and prognostic factors.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27185207",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.. American journal of hematology (2016 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27185207/",
    "drug": "decitabine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of \u223c30-40% and complete remission rates of \u223c7-17%.",
      "The GFM model segregates patients into 3 groups ... with respective median survivals of 56 (low), 27.4 (intermediate), and 9.2 (high) months.",
      "The MMM is based on ... This model stratifies patients into four groups; high (\u22653 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor) and low (no risk factors), with median survivals of 16, 31, 59, and 97\u00a0months, respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study reports overall response rates of 30-40% for hypomethylating agents, with complete remission rates of 7-17%.  The GFM and MMM prognostic models provide overall survival medians ranging from 9.2 to 97 months depending on risk factors.  No PFS data was explicitly mentioned.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26968357",
    "citation": "Guillermo Garcia-Manero et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.. The Lancet. Oncology (2016 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26968357/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 8.2,
    "total_patients": 299,
    "cmml_patients": null,
    "supporting_quotes": [
      "From Dec 13, 2010, to Aug 15, 2013, we enrolled 299 patients: 199 assigned to rigosertib, 100 assigned to best supportive care.",
      "Median follow-up was 19\u00b75 months (IQR 11\u00b79-27\u00b73).",
      "As of Feb 1, 2014, median overall survival was 8\u00b72 months (95% CI 6\u00b71-10\u00b71) in the rigosertib group and 5\u00b79 months (4\u00b71-9\u00b73) in the best supportive care group (hazard ratio 0\u00b787, 95% CI 0\u00b767-1\u00b714; p=0\u00b733)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed a median overall survival of 8.2 months in the rigosertib group and 5.9 months in the best supportive care group.  The difference was not statistically significant (p=0.33). No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26908133",
    "citation": "Jane Merlevede et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.. Nature communications (2016 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26908133/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The study focuses on the mutational landscape and epigenetic effects of hypomethylating agents in CMML, not providing any response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "26860635",
    "citation": "Marjan Cruijsen et al. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2016 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26860635/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 14.78,
    "total_patients": 30,
    "cmml_patients": 2,
    "supporting_quotes": [
      "At a median follow-up of 443 days, the overall survival was 53%",
      "Thirty patients were enrolled, including 11 with MDS, 2 with CMML, and 17 with AML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall survival rate of 53% at a median follow-up of 443 days (approximately 14.8 months).  No other response rates or survival metrics are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26462118",
    "citation": "Salih Subari et al. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia.. Leukemia & lymphoma (2016 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26462118/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No quantitative efficacy data (response rates or survival data) were found in the provided title and abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25822018",
    "citation": "Kristen Meldi et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.. The Journal of clinical investigation (2015 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25822018/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 40,
    "cmml_patients": 40,
    "supporting_quotes": [
      "Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study identified 167 differentially methylated regions (DMRs) that distinguished responders from nonresponders to decitabine.  No overall response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25735917",
    "citation": "St\u00e9phanie Harel et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.. Leukemia research (2015 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25735917/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": 16.7,
    "overall_response_rate": 19.4,
    "progression_free_survival_median": null,
    "overall_survival_median": 7.3,
    "total_patients": 36,
    "cmml_patients": null,
    "supporting_quotes": [
      "Seven (19.4%) patients were responders including 3 marrow CR (mCR), 2 stable disease (SD) with HI-E, 1 SD with HI-N and HI-P and 1 SD with HI-N.",
      "Median OS from onset of decitabine was 7.3 months, without significant difference between responders and non-responders.",
      "Treatment with decitabine after azacitidine failure yielded modest ORR (19.4%) with short response duration and poor OS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Decitabine treatment after azacitidine failure in high-risk MDS and CMML patients showed a modest overall response rate of 19.4%, with a median overall survival of 7.3 months.  Marrow complete response rate was 16.7%.  Response duration was generally short.",
    "has_efficacy_data": true
  },
  {
    "pmid": "25663885",
    "citation": "Qi Deng et al. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.. Oncology letters (2015 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25663885/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 70-year-old male was admitted with fever, pruritus and weakness that had been apparent for two weeks, and a two-year history of monocytosis (22.5-27.0%).",
      "The present study describes a case of complete remission in an elderly patient with AML transformed from chronic myelomonocytic leukemia (CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of complete remission (CR) in a patient with AML transformed from CMML treated with a combination regimen.  No overall response rate, survival data, or other response rates are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25555161",
    "citation": "M M Patnaik et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.. Blood cancer journal (2015 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25555161/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "Extraction failed",
    "extraction_confidence": null,
    "efficacy_summary": "504 Deadline Exceeded",
    "has_efficacy_data": false
  },
  {
    "pmid": "24653636",
    "citation": "Hee-Jun Kim et al. A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia.. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu (2014 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24653636/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 73-year-old male patient was brought to division of hematology for evaluation of leukocytosis. He was diagnosed with CMML and treated with decitabine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on a single CMML patient treated with decitabine;  no response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "24270737",
    "citation": "H Yang et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.. Leukemia (2014 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24270737/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 124,
    "cmml_patients": null,
    "supporting_quotes": [
      "We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study focuses on gene expression changes (PD-L1, PD-L2, PD-1, CTLA4) in response to hypomethylating agents in MDS, CMML, and AML.  While it mentions that patients resistant to therapy had higher gene expression increases, no response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "24261579",
    "citation": "D Shah et al. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.. Haemophilia : the official journal of the World Federation of Hemophilia (2014 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24261579/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "This report describes a rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia (CMML) successfully treated with decitabine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case of CMML successfully treated with decitabine.  No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23963888",
    "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.. American journal of hematology (2013 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23963888/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 18.5,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The median survival was 32 months, 18.5 months and 10 months in the low, intermediate, and high-risk groups, respectively.",
      "After a median follow-up of 2.5 years, survival ranged from not reached in the low-risk group to 14.4 months in the high-risk group."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The Mayo model showed median overall survival of 32, 18.5, and 10 months across low, intermediate, and high-risk groups, respectively. The GFM score showed survival ranging from not reached to 14.4 months (high risk group) after a median follow-up of 2.5 years.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23671007",
    "citation": "Ellen J B Derissen et al. Concise drug review: azacitidine and decitabine.. The oncologist (2013)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23671007/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract only mentions that azacitidine and decitabine are used in treating CMML, but it does not provide any specific clinical efficacy data such as response rates or survival metrics.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23336938",
    "citation": "Maria Teresa Voso et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.. European journal of haematology (2013 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23336938/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": 5.4,
    "overall_survival_median": null,
    "total_patients": 13,
    "cmml_patients": null,
    "supporting_quotes": [
      "We reviewed outcomes in 13 patients who discontinued azacitidine (decitabine in one patient) while still responding to the treatment.",
      "Most patients rapidly relapsed; median time to progression was 5.4 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows a median progression-free survival of 5.4 months after azacitidine treatment discontinuation in 13 patients with MDS or CMML.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23262795",
    "citation": "Jun Ho Yi et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.. Annals of hematology (2013 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23262795/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 26.4,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 61,
    "cmml_patients": null,
    "supporting_quotes": [
      "Best response was noted in 14 patients (26.4 %) out of 53 evaluated patients including 12 CR and two PR with median follow-up of 21.6 months.",
      "A total of 61 MDS/CMML patients treated with decitabine were evaluated"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Decitabine showed an overall response rate of 26.4% (14/53 patients) in this study of MDS/CMML patients.  The study also showed a trend towards worse overall survival in patients with abnormal SNP lesions.  Median survival times were not reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "22911588",
    "citation": "J C Sousa et al. Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.. Genetics and molecular research : GMR (2012 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22911588/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We present a case of chronic myelomonocytic leukemia with normal cytogenetics at diagnosis treated with decitabine (with good response)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study presents a single case of CMML treated with decitabine showing a good response.  No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22615103",
    "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.. American journal of hematology (2012 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22615103/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract provides background information on CMML diagnosis, risk stratification, and treatment approaches, but it does not report any clinical efficacy metrics such as response rates or survival data from specific clinical trials.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22555082",
    "citation": "Hannah B Trickett et al. Azacitidine-associated Sweet's syndrome.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2012 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22555082/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 1,
    "supporting_quotes": [
      "In one of two cases of probable azacitidine-related Sweet's syndrome reported here, a 64-year-old man with myelodysplastic syndrome (MDS) developed a severe erythematous and nodular rash with peeling on his arms, legs, and face after receiving the drug (75 mg/m(2) subcutaneously daily) for three days; the second case involved a 67-year-old man with chronic myelomonocytic leukemia (CMML) who experienced a similar skin rash, as well as chills and an elevated body temperature, after five days of treatment with azacitidine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports two cases of Sweet's syndrome associated with azacitidine treatment. One patient had MDS, and the other had CMML.  No efficacy data on CMML treatment itself is provided, only the occurrence of a side effect and its response to corticosteroid treatment.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22213878",
    "citation": "Li Wang et al. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2011 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22213878/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 2,
    "supporting_quotes": [
      "Treatment of two chronic myelomonocytic leukemia patients with Decitabine"
    ],
    "data_source_location": "title",
    "extraction_confidence": 100,
    "efficacy_summary": "The study only provides the number of patients treated (two with CMML).  No response rates or survival data are reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "21828134",
    "citation": "Thorsten Braun et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.. Blood (2011 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21828134/",
    "drug": "decitabine",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": 21.0,
    "overall_response_rate": 38.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 39,
    "cmml_patients": 39,
    "supporting_quotes": [
      "Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%).",
      "With a median follow-up of 23 months, overall survival was 48% at 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 38% to decitabine in 39 patients with advanced CMML.  Complete responses were observed in 10% of patients, and marrow responses in 21%. Overall survival at 2 years was 48%.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21656746",
    "citation": "Rubens Costa et al. Activity of azacitidine in chronic myelomonocytic leukemia.. Cancer (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21656746/",
    "drug": "decitabine",
    "complete_response": 11.0,
    "partial_response": 3.0,
    "marrow_complete_response": null,
    "overall_response_rate": 39.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 12.0,
    "total_patients": 38,
    "cmml_patients": 38,
    "supporting_quotes": [
      "The overall response rate was 39% (14 of 36); complete response (CR) rate was 11% (4 of 36); partial response (PR) rate was 3% (1 of 36); hematologic improvement (HI) was 25% (9 of 36).",
      "The median overall survival was 12 months.",
      "There was a statistically significant overall survival advantage in responders compared with nonresponders: 15.5 months versus 9 months, respectively (P = .04)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Azacitidine demonstrated an overall response rate of 39% in 38 CMML patients, with complete and partial response rates of 11% and 3%, respectively. Median overall survival was 12 months, significantly longer for responders (15.5 months) compared to non-responders (9 months).",
    "has_efficacy_data": true
  },
  {
    "pmid": "21537084",
    "citation": "Romain Aucagne et al. Transcription intermediary factor 1\u03b3 is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.. The Journal of clinical investigation (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21537084/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "TIF1\u03b3 was almost undetectable in leukemic cells of 35% of CMML patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports that TIF1\u03b3 was undetectable in 35% of CMML patients.  No other response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "21425542",
    "citation": "Eric Solary et al. [Myeloproliferative/myelodysplastic syndromes].. La Revue du praticien (2010 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21425542/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The prognosis remains poor, with a median survival lower than 24 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median survival lower than 24 months.  No other efficacy data (response rates, PFS) are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20929328",
    "citation": "Marcelo Iastrebner et al. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.. Leukemia & lymphoma (2010 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20929328/",
    "drug": "decitabine",
    "complete_response": 19.0,
    "partial_response": 8.0,
    "marrow_complete_response": 4.0,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 106,
    "cmml_patients": null,
    "supporting_quotes": [
      "Of 106 patients who received decitabine 20 mg/m(2) intravenously over 1\u2009h once daily for 5 days in 4-week cycles, 99 patients were evaluable after receiving at least two cycles.",
      "The overall improvement rate was 35% (19% complete response +4% marrow complete response +4% partial response +8% hematologic improvement).",
      "Overall survival at 2 years was 71%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Decitabine demonstrated an overall response rate of 35% including 19% complete response, 4% marrow complete response, and 8% partial response.  Two-year overall survival was 71%.  Progression-free survival data was not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20564137",
    "citation": "Elias Jabbour et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.. Cancer (2010 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20564137/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 4.3,
    "total_patients": 87,
    "cmml_patients": 20,
    "supporting_quotes": [
      "Data from 87 patients with MDS (n=67) and chronic myelomonocytic leukemia (n=.20) after failure of decitabine regimens were reviewed.",
      "After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports a median overall survival of 4.3 months for patients with MDS and CMML after decitabine failure.  The 12-month survival rate was 28%.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20511166",
    "citation": "G Nicolas Batty et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.. Clinical lymphoma, myeloma & leukemia (2010 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20511166/",
    "drug": "decitabine",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 63.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 8.6,
    "total_patients": 41,
    "cmml_patients": 9,
    "supporting_quotes": [
      "The overall response rate was 63%, and 4 patients (10%) achieved a complete response.",
      "The overall survival (OS) at 18 months was 12%, and the median OS was 8.6 months.",
      "We reviewed 41 patients with a diagnosis of acute myeloid leukemia (n = 17), myelodysplastic syndromes (n = 15), and chronic myelomonocytic leukemia (n = 9) who had RI and were receiving therapy with azacitidine or decitabine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 63% with a 10% complete response rate in patients with renal insufficiency receiving hypomethylating agents. Median overall survival was 8.6 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "18496432",
    "citation": "Michael R Hinckley et al. Generalized granuloma annulare as an initial manifestation of chronic myelomonocytic leukemia: a report of 2 cases.. The American Journal of dermatopathology (2008 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/18496432/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 2,
    "supporting_quotes": [
      "Two patients with generalized granuloma annulare as an initial manifestation of chronic myelomonocytic leukemia are herein described."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports two cases of CMML presenting with granuloma annulare; no efficacy data (response rates or survival) are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "18179966",
    "citation": "Elizabeth A Griffiths et al. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.. Seminars in hematology (2008 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/18179966/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 30.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract reports response rates between 20% and 40% from randomized clinical trials of 5-azacitidine and 5-aza-2'-deoxyazacytidine in patients with no prior standard of care for MDS, including CMML.  Specific response types (CR, PR, mCR) and survival data are not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "18055864",
    "citation": "Yasuhiro Oki et al. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.. Blood (2008 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/18055864/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": 3,
    "supporting_quotes": [
      "Two patients had complete disappearance of mutant alleles and sustained clinical remissions.",
      "In another patient, mutant allele was detectable at clinical remission, which lasted for 8 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study reports clinical remission in two patients with complete disappearance of mutant alleles, and one patient with detectable mutant alleles in clinical remission for 8 months.  No overall response rates or survival data are explicitly provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "17881052",
    "citation": "P W Wijermans et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).. Leukemia research (2008 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17881052/",
    "drug": "decitabine",
    "complete_response": 14.0,
    "partial_response": 11.0,
    "marrow_complete_response": null,
    "overall_response_rate": 25.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 31,
    "cmml_patients": 31,
    "supporting_quotes": [
      "The ORR was 25% (14% CR+11% PR)",
      "A total of 31 patients diagnosed with CMML are included in this review."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Decitabine demonstrated an overall response rate of 25% in 31 CMML patients, with complete response and partial response rates of 14% and 11%, respectively.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17701595",
    "citation": "David P Steensma et al. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.. Leukemia & lymphoma (2007 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17701595/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "17644750",
    "citation": "Aristoteles A N Giagounidis Decitabine dosage in myelodysplastic syndromes.. Blood (2007 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17644750/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "17612710",
    "citation": "Kalpana Ghoshal et al. DNA methyltransferases as targets for cancer therapy.. Drugs of today (Barcelona, Spain : 1998) (2007 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17612710/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Clinical trials have shown that both drugs have therapeutic potential against leukemia such as MDS, acute myeloid leukemia, chronic myelogenous leukemia and chronic myelomonocytic leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions that clinical trials showed therapeutic potential of Vidaza and Dacogen against CMML, but provides no specific efficacy metrics (response rates or survival data).",
    "has_efficacy_data": false
  },
  {
    "pmid": "17315156",
    "citation": "Hagop M Kantarjian et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.. Cancer (2007 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17315156/",
    "drug": "decitabine",
    "complete_response": 43.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 22.0,
    "total_patients": 491,
    "cmml_patients": null,
    "supporting_quotes": [
      "The complete remission (CR) rate according to AML criteria was 43% with decitabine, 46% with intensive chemotherapy in Group A, and 52% with intensive chemotherapy in Group B.",
      "Survival was better with decitabine versus intensive chemotherapy in Group A (median survival: 22 months vs 12 months; P < .001)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Decitabine showed a higher complete remission rate (43%) compared to intensive chemotherapy (46% in matched group A, 52% in unmatched group B) and significantly better overall survival (median 22 months vs 12 months for intensive chemotherapy in group A).",
    "has_efficacy_data": true
  },
  {
    "pmid": "17313156",
    "citation": "David P Steensma et al. Risk-based management of myelodysplastic syndrome.. Oncology (Williston Park, N.Y.) (2007 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17313156/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract discusses MDS treatment options and their approval status but does not provide any specific clinical efficacy metrics such as response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "17219444",
    "citation": "Ahmed Aribi et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.. Cancer (2007 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17219444/",
    "drug": "decitabine",
    "complete_response": 58.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 69.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 19.0,
    "total_patients": 19,
    "cmml_patients": 19,
    "supporting_quotes": [
      "Overall, 11 patients (58%) achieved complete response (CR) and 2 (11%) had hematologic improvement (HI), for an overall response rate of 69% according to the modified International Working Group (IWG) criteria.",
      "Median survival was 19 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Decitabine showed a 69% overall response rate in 19 CMML patients, with a 58% complete response rate. Median survival was 19 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17133405",
    "citation": "Hagop M Kantarjian et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.. Cancer (2007 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17133405/",
    "drug": "decitabine",
    "complete_response": 35.0,
    "partial_response": 2.0,
    "marrow_complete_response": 23.0,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 22,
    "total_patients": 115,
    "cmml_patients": null,
    "supporting_quotes": [
      "Overall, 80 patients (70%) achieved a response according to the modified International Working Group criteria (IWG): complete response (CR), 40 patients (35%); partial response, 2 patients (2%); bone marrow CR with or without other hematologic improvements (HI), 26 patients (23%); and other HI, 12 patients (10%).",
      "The median survival was 22 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows a 70% overall response rate to decitabine in higher-risk MDS patients.  Complete response was achieved in 35%, partial response in 2%, and marrow complete response in 23%. Median overall survival was 22 months.  No data on CMML patients specifically is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16955510",
    "citation": "Alfonso Quintas-Cardama et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.. Cancer (2006 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16955510/",
    "drug": "decitabine",
    "complete_response": 11.0,
    "partial_response": 16.0,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 44,
    "cmml_patients": 32,
    "supporting_quotes": [
      "Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%.",
      "Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m(2) orally daily 5 days a week, every 4 to 6 weeks."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study showed an overall response rate of 41% in patients with MDS and CMML treated with 9-NC, with 11% achieving complete response and 16% achieving partial response.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16882708",
    "citation": "Hagop Kantarjian et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (2007 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16882708/",
    "drug": "decitabine",
    "complete_response": 34.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 73.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 95,
    "cmml_patients": 18,
    "supporting_quotes": [
      "Overall, 32 patients (34%) achieved a complete response (CR), and 69 (73%) had an objective response by the new modified International Working Group criteria.",
      "Ninety-five patients were treated (77 with MDS, and 18 with CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 73% using the modified International Working Group criteria, with a complete response rate of 34%.  The 5-day intravenous schedule showed the highest complete response rate at 39%.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16464494",
    "citation": "M Daskalakis et al. Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.. Leukemia research (2006 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16464494/",
    "drug": "decitabine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 103,
    "cmml_patients": 5,
    "supporting_quotes": [
      "Among 103 consecutive MDS patients diagnosed and karyotyped at the Albert-Ludwigs University of Freiburg (ALU) between 1993 and 1999, two chronic myelomonocytic leukemias (CMMoL) displayed trisomy 19 (+19) as the sole chromosomal abnormality.",
      "Three further CMMoL cases with +19 as the single abnormality, two of which previously reported, were collected from other centers."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on five CMML patients with trisomy 19.  Treatment varied (Decitabine, steroids, hydroxyurea, daunorubicin/Ara-C). Transformation to AML occurred in three patients at 26, 12, and 22 months post-diagnosis. No response rates or survival data are provided.",
    "has_efficacy_data": false
  }
]